SweetWater Brewing Gives Fans the Chance to Win Tickets to Their Dream Show at AEG Venues Across Georgia

Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West

GlobeNewsWire • Oct 15, 2026

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?

Canopy Growth maintains a strategic focus on premium cannabis products and European medical distribution. Tilray Brands has expanded into the craft beverage and wellness markets to diversify its revenue streams.

The Motley Fool • Oct 15, 2026

BrewDog Acquisition Boosts Tilray's Q1 Performance

Tilray reported Q1-2027 financial results last week with increasing revenue from its BrewDog operations; Cannabis revenue decreased. The company expects its new beer assets along with its international cannabis operations to continue to drive growth. The company reported a net loss and negative free cash flow.

Seeking Alpha • Oct 13, 2026

Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal's National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical's EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.

GlobeNewsWire • Oct 13, 2026

3 Huge Red Flags From Tilray's Q1 Earnings Report

Tilray's cash burn continues to be a big problem for investors. The business has been growing through acquisitions, and while that can boost the top line, it can also lead to significantly higher expenses.

The Motley Fool • Oct 12, 2026

Tilray Q1: Not Looking Good, Remains A 'Hold'

Tilray reported disappointing fiscal Q1 results, missing revenue estimates despite management highlighting record sales. TLRY's revenue growth was driven solely by the BrewDog acquisition; core cannabis sales declined 13%, and the adjusted bottom line swung to a loss. Cash burn surged to $23.4 million, and share dilution remains severe, with shares outstanding up over 31% year-over-year.

Seeking Alpha • Oct 12, 2026

3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices

Tilray's financial results have been weak for years. The company operates in an uncertain industry.

The Motley Fool • Oct 10, 2026

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

Canopy Growth is refining its focus on medical and adult-use markets while managing its U.S. expansion strategy through Canopy USA. Tilray Brands has diversified its revenue stream significantly through a large craft beer and beverage portfolio alongside its global cannabis operations.

The Motley Fool • Oct 10, 2026

Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform

Tilray Brands TodayTLRYTilray Brands$3.44 -0.15 (-4.04%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$3.38▼$20.20Price Target$6.38Add to WatchlistWhen investors hear talk of U.S. cannabis reform, they often look at major Canadian operators.

MarketBeat • Oct 9, 2026

Tilray Brands Not Dependent on Single Market, CEO Highlights Multiple Growth Engines

Tilray Brands Inc. (NASDAQ:TLRY) reported a first-quarter 2027 adjusted loss of 2 cents per share on Thursday, beating the consensus loss of 20 cents.

Benzinga • Oct 8, 2026